| http://www.w3.org/ns/prov#value | - ???We are pleased that the Cystic Fibrosis Foundation has selected TRIOLEX based on the criteria set forth in our collaboration agreement for developing a novel oral anti-inflammatory drug candidate,??? said Richard B. Hollis, Chairman and CEO, Hollis-Eden Pharmaceuticals, Inc. ???Cystic Fibrosis is a form of chronic obstructive pulmonary disease that causes pulmonary inflammation, and we are extr
|
